My main research interests are in genital and urinary cancers, and I lead a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies.
MPDL3280A (Anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 515(7528):558-62. PMID: 25428503
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol (2011) 29(16):2178-84. PMID: 21444870
Sequential FDG-PET/CT as a biomarker of response to sunitinib in metastatic clear cell renal cancer. Clin Cancer Res (2011) 17(18):6021-8. PMID: 21742806
Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol (2009) 27(6):884-90. PMID: 19114688
I am the lead for solid tumor research at Barts Cancer Institute. I also lead the genitourinary (GU) cancer group at BCI.
My work focuses on a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies. They exploit functional imaging and tissue collection.
Alongside these trials, our research focuses on correlation of novel biomarkers and aims to define markers that are of prognostic value and can predict response or resistance to therapy.
I have written over 100 peer review papers in this area and have grant income from national and international funding bodies.
I am on the editorial board of a number of journals and am part of the faculty for the major global oncology meetings.
Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. Martini A, Jia R, Ferket BS et al. Cancer (2019) (2)
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. Albiges L, Powles T, Staehler M et al. Eur Urol (2019) (2)
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Ljungberg B, Albiges L, Abu-Ghanem Y et al. Eur Urol (2019) 75(2) 799-810
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. Gonzalez-Exposito R, Semiannikova M, Griffiths B et al. J Immunother Cancer (2019) 7(2) 101
Single-centre Experience of Patients with Metastatic Urothelial Cancer Treated with Chemotherapy Following Immune Checkpoint Inhibition. Lam JM, Liu WK, Powles T et al. Eur Urol Oncol (2019) (2)
Imaging in Suspected Renal-Cell Carcinoma: Systematic Review. Vogel C, Ziegelmüller B, Ljungberg B et al. Clin Genitourin Cancer (2019) 17(2) e345-e355
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. Bamias A, Tzannis K, Bamia C et al. Oncologist (2019) (2)
The adjuvant treatment of kidney cancer: a multidisciplinary outlook. Porta C, Cosmai L, Leibovich BC et al. Nat Rev Nephrol (2019) (2)
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. Sternberg CN, Loriot Y, James N et al. Eur Urol (2019) (2)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. Rini BI, Plimack ER, Stus V et al. N Engl J Med (2019) 380(2) 1116-1127
I qualified from St Bartholomew’s Medical School in 1996 and trained in medical oncology at Imperial College. I completed post-graduate training in oncology in 2005 and received an MD from the University of London in 2006. My thesis was in mechanisms of resistance to therapy in urology cancers.